What we’re reading, December 16, 2016: consumers now have until December 19 to enroll in a marketplace plan for coverage starting on January 1; 20 states file lawsuit against 6 pharmaceutical companies alleging generic price fixing; women who were tested for the BRCA mutation gene after Angelina Jolie’s announcement may not have been at high risk to begin with.
Consumers now have more time to sign up for Affordable Care Act marketplace plans, as HHS has extended the deadline for consumers to sign up for coverage starting on January 1. Nearly 1 million people were still in the process of enrolling as the original deadline approached last night, so officials announced the sign-up period would be extended until midnight on December 19, citing the “extraordinary demand at HealthCare.gov” in recent days.
Twenty states have filed a civil lawsuit against 6 generic drug manufacturers, including Mylan NV and Teva Pharmaceuticals. The suit, led by Connecticut, alleges that Heritage Pharmaceuticals was the “ring leader,” as it conspired with the other manufacturers to fix prices and allocate market shares. Connecticut Attorney General George Jepsen told Reuters that prosecutors “believe that this is the tip of the iceberg” and there is “widespread and pervasive” price fixing in the generic drug industry.
Angelina Jolie’s 2013 editorial in The New York Times announcing that she had undergone a preventive mastectomy after testing positive for the BRCA gene caused a spike in the number of women seeking the genetic test, according to a study in BMJ. Researchers found a 64% relative increase in BRCA tests from the 15 days before Jolie’s announcement to the 15 days after. However, mastectomy rates were decreased among women who had a BRCA test after the editorial was published, “suggesting that women who underwent tests as a result of the editorial had a lower pre-test probability of having the BRCA mutation than women tested before the editorial.”
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen